Some crucial peptide inhibitors that are currently in use for neurodegenerative disorders include Aβ (16–20) KLVFF for Alzheimer’s disease, NAPVSIPQ (NAP) and DNL201 (an LRRK2 inhibitor) for Parkinson’s disease [185], Vasoactive Intestinal Peptides (VIP) for Huntington’s disease, and Polyglutamine Binding Peptide-1(QBP1) for Dentatorubral-pallidoluysian atrophy (DRPLA) [181]. Here, VIP is linked to Dentatorubral pallidoluysian atrophy.